PSA

We have just published our latest review about the role of KLK3 as an activator of VEGF-C and VEGF-D in prostate cancer. Prostate cancer is one of the most common cancers in males. It is not a question whether you will get it but only when.

The International Symposium on Kallikreins and Kallikrein-related Peptidases (ISK) took place on September 25.-27. in Prague.

There is a nice Finnish language abstract about our recent finding that PSA (Prostate-specific antigen) activates VEGF-C and VEGF-D in the Finnish medical journal Duodecim.